Meeting
2024 ASCO Breakthrough
Characterization of estrogen receptor mutant breast cancer in 3D cell culture.
Authors
Olivia Mayer
Texas College of Osteopathic Medicine, Fort Worth, TX
Olivia Mayer , Jordan Wright , Caroline Rinderle , Bruce Bunnell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Novel preclinical models
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 14)
DOI
10.1200/JCO.2024.42.23_suppl.14
Abstract #
14
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.
First Author: Nicholas Mai
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei
Poster
2012 Breast Cancer Symposium
Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status.
First Author: Cindy Christopherson
Poster
2024 ASCO Annual Meeting
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.
First Author: Nicholas Mai